Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.37 | 0.04 | 0.02 | -0.05 |
| FCF Yield | -116.25% | -134.84% | -281.68% | -129.22% |
| EV / EBITDA | -0.01 | 1.19 | -5.85 | -0.09 |
| Quality | ||||
| ROIC | -134.56% | -57.84% | -309.38% | -262.46% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.03 | 2.38 | 7.34 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.22% | -4.61% | -23.57% | 1,925,769.62% |
| Free Cash Flow Growth | -11.64% | 59.65% | 26.66% | -2.21% |
| Safety | ||||
| Net Debt / EBITDA | 0.81 | 1.90 | -14.36 | 0.61 |
| Interest Coverage | -586,543.48 | -6,216.50 | -19.44 | -20.41 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 12.07 | 1.46 | 15.48 |